NEA 14 Gp, Ltd., 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 3,000,000 shares at $1.67 ($5.0M) on 2018-09-07, disclosed to the SEC on 2018-09-10.
Open-market purchase of $5.0M ADAP by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| Filing → |
| ADAP | BUY | 2018-03-23 | $4.8M | — | Filing → |
| MRSN | BUY | 2017-07-06 | $15.0M | — | Filing → |
| ADAP | BUY | 2017-03-28 | $9.0M | — | Filing → |